Microsoft word - rule 1843 2 - classification of drug substances.doc
1843.2. Classification of Drug Substances.
The Board, the board of stewards, the hearing officer, or the administrative law judge, when adjudicating a hearing for a violation of Business and Professions Code section 19581, shall consider the classification of the substance as referenced in the California Horse Racing Board (CHRB) Penalty Categories Listing by Classification (Revised 01/08), hereby incorporated by reference, which is based on the Association of Racing Commissioners International (ARCI) Uniform Classification Guidelines for Foreign Substances (4/05), as modified by the Board. NOTE: Authority cited: Sections 19580, 19581 and 19582, Business and Professions Code. Reference: Sections 19580, 19581 and 19582, Business and Professions Code. HISTORY: 1. New rule filed 8-7-95; effective 9-6-95. 2. Amendment filed 12-6-99; effective 12-6-99. 3. Amendment filed 5-23-08; effective 5-23-08
California Horse Racing Board (CHRB) Penalty Categories Listing by Classification Class 1: Stimulant and depressant drugs that have the highest potential to affect performance and that have no generally accepted medical use in the
racing horse. Many of these agents are Drug Enforcement Agency (DEA) schedule II substances. These include the following drugs and their metabolites:
Opiates, opium derivatives, synthetic opioids and psychoactive drugs, amphetamines and amphetamine-like drugs as well as related drugs, including but not
limited to apmorphine, nikethamide, mazindol, pemoline, and pentylenetetrazol.
Trade Name Drug Class Trade Name Drug Class Penalty Class Listing by Classification Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse.
Drug Trade Drug Trade Listing by Classification Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse.
Drug Trade Drug Trade Listing by Classification Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse.
Drug Trade Drug Trade Listing by Classification Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse.
Drug Trade Drug Trade Listing by Classification Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse.
Drug Trade Drug Trade Listing by Classification Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse.
Drug Trade Drug Trade Listing by Classification Class 2: Drugs that have a high potential to affect performance, but less of a potential than Class 1. These drugs are 1) not generally accepted as
therapeutic agents in racing horses, or 2) they are therapeutic agents that have a high potential for abuse.
Drug Trade Drug Trade Valdecoxib Listing by Classification Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to
affect performance than drugs in Class 2.
Drug Trade Drug Trade Listing by Classification Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to
affect performance than drugs in Class 2.
Drug Trade Drug Trade Listing by Classification Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to
affect performance than drugs in Class 2.
Drug Trade Drug Trade Listing by Classification Class 3: Drugs that may or may not have generally accepted medical use in the racing horse, but the pharmacology of which suggests less potential to
affect performance than drugs in Class 2.
Drug Trade Penalty Class
metabolite, Trandolaprilat) Trenbolone Finoplix
Listing by Classification Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3. Drug Trade Drug Trade Listing by Classification Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3. Drug Trade Drug Trade Listing by Classification Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3. Drug Trade Drug Trade Listing by Classification Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3. Drug Trade Drug Trade Listing by Classification Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3. Drug Trade Drug Trade Listing by Classification Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3. Drug Trade Drug Trade Listing by Classification Class 5: This class includes the following therapeutic medications for which concentration limits have been established. Drug Trade Penalty Class
NEWS RELEASE FOR IMMEDIATE RELEASE For more information, contact: Rick Ryan, Vice President of Business Development(636) 328-6610 DR. JOHN TALLEY HEADLINES NEW MEDICINAL CHEMISTRY PROVIDER Inventor of Celebrex™ serves as chief scientific officer for St. Louis-based SARmont ST. LOUIS (May 25, 2011) – The scientific mind behind pharmaceutical market- changers Celebrex™ and three
Clinical Chemistry 48:91497–1504 (2002)Limited Sampling Strategy for the Estimation ofMycophenolic Acid Area under the Curve in AdultTomasz Pawinski,1 Mike Hale,2 Magda Korecka,1 William E. Fitzsimmons,3 and Background: Significant relationships between the my- prediction error for the AUC0–12h values not included in cophenolic acid (MPA) area under the concentration– the